oncology
Breast Cancer

Time to stop using PFS outcomes for antiangiogenesis therapies: oncologist

An Australian oncologist has questioned whether further trials of the antiangiogenesis therapy bevacizumab in metastatic cancers are justified in the absence of an overall survival benefit. Associate Professor Ian Haines of Monash University says the results from numerous trials of the anti-VEGF inhibitor in nine different cancer indications have only shown benefit in the ‘inferior’ ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic